# AstraZeneca PLC (AZN.L) fundamentals

Data as of 2026-09-08. LSE, United Kingdom. Sector: Healthcare / Pharmaceuticals. Price 11974p, market value 185.7 billionp.

## Valuation
- **P/E (trailing): 24.3×**. AstraZeneca PLC trades at 24.3× trailing earnings. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 14.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.29**. A PEG of 0.29 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.1×**. Each dollar of revenue is priced at 4.1×.
- **Price / book: 5.0×**. The shares trade at 5.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 13.4×**. Enterprise value is 13.4× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.4%** (5-yr avg 0.0%). Free cash flow equals 2.4% of the market value, above its five-year average of 0.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 4.1%**. The inverse of the P/E: 4.1% of the price is earned each year.

## Profitability
- **Gross margin: 81.8%**. AstraZeneca PLC keeps 81.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 22.8%**. 22.8% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 17.4%**. 17.4% of each dollar of sales reaches the bottom line.
- **Return on equity: 21.0%**. 21.0% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 16.0%**. Return on all capital, debt included, is 16.0%: comfortably above what that capital costs.
- **Return on assets: 9.2%**. Each dollar of assets produces 9.2% of profit.

## Growth
- **Revenue growth (1 yr): 10.9%** (3-yr 9.9%/yr, 5-yr 14.9%/yr). Revenue grew 10.9% over the last year, against 14.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 48.3%** (3-yr 46.0%/yr, 5-yr 20.4%/yr). Earnings per share rose 48.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 6.2%/yr**. Free cash flow has compounded at 6.2% a year over three years, lagging earnings: check whether profits are turning into cash.

## Financial health
- **Debt to equity: 0.61**. Debt is 0.61 times equity, moderate leverage.
- **Net debt / EBITDA: 1.2×**. It would take 1.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 8.0×**. Operating profit covers interest 8.0× over, a safe margin.
- **Current ratio: 0.94** (quick 0.72). Current liabilities exceed current assets, so the company depends on ongoing cash generation or refinancing to pay the next year's bills.
- **Altman Z-score: 3.20**. A Z-score of 3.20 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 9/9**. 9 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 1.98%** (2p per share, trailing). AstraZeneca PLC yields 1.98%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 49%** (81% of free cash flow). 49% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.
- **Dividend growth (5 yr): 2.5%/yr** (1-yr 4.8%). The dividend has grown 2.5% a year over five years.
- **Shareholder yield: 2.2%**. Dividends plus net buybacks return 2.2% of the market value a year.

## Analyst view
- **Analyst consensus: buy** (22 analysts). 22 analysts cover AstraZeneca PLC; the consensus is buy, with an average price target of 15745p (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -0.4%** (YTD -12.7%, 3-mo -12.8%). The shares are down 0.4% over twelve months including dividends.
- **From 52-week high: -23.9%** (21.0% above the low). Trading 24% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 1.13** (volatility 28%). Beta of 1.13 against the FTSE All-Share: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AZN.L · Page: https://foliofundamentals.com/stocks/azn.l

Not investment advice.